Skip to content

RADX

Radiopharm Theranostics Ltd.

NASDAQ · Healthcare · Biotechnology · AU

$0.96
−6.50%
Ask drillr

Year over year

Reported trailing growth

Revenue
—
EBITDA
—
EBIT
—
EPS
—
Free cash flow
—
Operating cash flow
—

Forward estimates

Based on analyst estimates

Revenue
-26.9%
EBITDA
+103.5%
EPS
+99.8%

Three-year CAGR

Revenue
+110.0%
EBITDA
-80.7%
EBIT
-75.1%
Net income
-40.7%
EPS
+13.6%
Free cash flow
+100.0%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026